160 related articles for article (PubMed ID: 17990361)
1. In-vitro activation of cytotoxic T lymphocytes by fusion of mouse hepatocellular carcinoma cells and lymphotactin gene-modified dendritic cells.
Sheng XL; Zhang H
World J Gastroenterol; 2007 Nov; 13(44):5944-50. PubMed ID: 17990361
[TBL] [Abstract][Full Text] [Related]
2. Lymphotactin enhances the in-vitro immune efficacy of dendritoma formed by dendritic cells and mouse hepatocellular carcinoma cells.
Zhang H; Jiang GP; Zheng SS; Wu LH; Zhu F; Yang ZL
J Zhejiang Univ Sci; 2004 Oct; 5(10):1255-61. PubMed ID: 15362198
[TBL] [Abstract][Full Text] [Related]
3. [Antitumor effect of immunizations with fusions of dendritic and hepatocellular carcinoma cells in mice].
Zhang H; Zheng SS; Jiang GP; Zhou L; Xie HY
Zhonghua Gan Zang Bing Za Zhi; 2004 Nov; 12(11):648-51. PubMed ID: 15623369
[TBL] [Abstract][Full Text] [Related]
4. [Construction of eukaryotic expression vector of mouse alpha-fetoprotein cDNA and its expression in dendritic cells and in vitro antitumor effect on hepatoma].
Zeng B; Lu FG; Liu XW; Yang DY; Fang WY; Wang J; Liao AJ; Shi W
Ai Zheng; 2005 Nov; 24(11):1332-7. PubMed ID: 16552958
[TBL] [Abstract][Full Text] [Related]
5. [Inducing hepatocellular carcinoma-specific cytotoxic T lymphocyte response using formed by fusion of FastDCs and allogeneic human hepatocellular carcinoma cells].
Guan X; Leng XS; Peng JR; Wei YH; Wang H; Yuan L
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3332-6. PubMed ID: 16409838
[TBL] [Abstract][Full Text] [Related]
6. [Immunization with dendritic cells infected with mTERT adenovirus vector effectively elicits immunity against mouse H22 hepatoma in vivo].
Jiang N; Wang GS; Li H; Zhang J; Zhang JF; Yi SH; Yi HM; Yang Y; Cai CJ; Lu MQ; Chen GH
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):405-9. PubMed ID: 19950546
[TBL] [Abstract][Full Text] [Related]
7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
8. Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity.
Huang Y; Mao Q; He J; Su J; Peng Y; Liang W; Hu Z; Zhou S; Lu X; Zhao Y
Sci Rep; 2017 Apr; 7():46544. PubMed ID: 28436481
[TBL] [Abstract][Full Text] [Related]
9. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
10. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
[TBL] [Abstract][Full Text] [Related]
11. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of antitumor effects of dendritic cells modified with different forms of hepatocellular cancer antigens].
He LX; Zhang GM; Feng ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jan; 21(1):100-2, 117. PubMed ID: 15629095
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of immunization with fusion of dendritic cells and hepatocellular carcinoma cells in mice.
Zhang H; Zheng SS; Jiang GP; Wu LH; Zhu F; Yang ZL
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):235-40. PubMed ID: 15138117
[TBL] [Abstract][Full Text] [Related]
14. [GM-CSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro].
He SB; Sun K; Wang L; Li DC; Zhang YY
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):410-4. PubMed ID: 20819479
[TBL] [Abstract][Full Text] [Related]
15. Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line.
Yin XY; Wang L; Lu MD; Li BJ; Huang JF
Hepatogastroenterology; 2008; 55(81):155-9. PubMed ID: 18507097
[TBL] [Abstract][Full Text] [Related]
16. [Construction of recombinant plasmid pIRES-GM-CSF-IL-21 and its therapeutic effect on orthotopically transplanted liver cancer in mice].
Cheng MR; Li Q; Hong XW; Ye T; He B; Cheng ZJ; Xu HZ; Zha BB
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):661-5. PubMed ID: 22340045
[TBL] [Abstract][Full Text] [Related]
17. [Immune response of HBsAg gene-modified dendritic cell-based vaccine in HepG2. 2. 15 hepatocellular carcinoma cells].
Yang JY; Liu WC; Cao DY; Si XM; Teng ZH
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):728-32. PubMed ID: 18396682
[TBL] [Abstract][Full Text] [Related]
18. Transduction of dendritic cells with recombinant adenovirus encoding HCA661 activates autologous cytotoxic T lymphocytes to target hepatoma cells.
Chan RC; Pang XW; Wang YD; Chen WF; Xie Y
Br J Cancer; 2004 Apr; 90(8):1636-43. PubMed ID: 15083197
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of CTLs induced by DCs loaded with ubiquitinated hepatitis B virus core antigen.
Chen JH; Yu YS; Chen XH; Liu HH; Zang GQ; Tang ZH
World J Gastroenterol; 2012 Mar; 18(12):1319-27. PubMed ID: 22493545
[TBL] [Abstract][Full Text] [Related]
20. In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells.
Koido S; Homma S; Hara E; Mitsunaga M; Namiki Y; Takahara A; Nagasaki E; Komita H; Sagawa Y; Ohkusa T; Fujise K; Gong J; Tajiri H
J Transl Med; 2008 Sep; 6():51. PubMed ID: 18793383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
